Placing Drug Strategies On A Solid Foundation For Success

The demand for drugs and therapeutics is growing rapidly alongside the globalization of healthcare. While the pharmaceutical industry’s core mission—delivering safe, effective, and affordable medicines to patients—remains unchanged, the way this mission is achieved is evolving.

Emerging pharma companies are increasingly driving innovation. Between 2011 and 2020, over half (55%) of FDA-approved medicines came from companies with annual revenues under $500 million, underscoring the growing influence of smaller players in drug development. At the same time, a focus on treatments for smaller, more targeted patient populations is increasing both the complexity and risk of drug development.

The push to bring new, more effective therapies to market faster, more safely, and more economically is driving innovative development strategies and business models. For small and mid-sized pharma companies, outsourcing has become an essential tool, enabling efficient commercialization while reducing risk.

This white paper explores the key trends shaping pharmaceutical manufacturing today and examines how these trends are reshaping traditional strategies and relationships with contract manufacturing organizations (CMOs). From complex compounds to novel therapies, we provide insights into how pharma companies can leverage CMOs to streamline development, enhance efficiency, and support successful outcomes from the earliest stages.